Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Mario Airoldi, Pietro Gabriele, Anna Maria Gabriele, Massimiliano Garzaro, Luca Raimondo, Fulvia Pedani, Fabio Beatrice, Giancarlo Pecorari, Carlo Giordano

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Aim of this study was the clinical evaluation of carboplatin-taxol combination in a neoadjuvant and concomitant setting with conventional radiotherapy in loco-regionally advanced nasopharyngeal carcinoma (A-NPC). Methods: Thirty patients were treated with three cycles of carboplatin (AUC6) plus taxol (175 mg/m 2) on day 1 every 3 weeks, followed by weekly carboplatin (AUC1) plus Taxol (60 mg/m2) and concomitant radiotherapy (70 Gy). Results: We observed the objective complete response rates of 33% (after chemotherapy) and 87% (after chemo-radiotherapy). Treatment tolerability and toxicity were controllable. Three- and five-year progression-free survival were 80 and 75%, respectively, and 3- and 5-year overall survival were 85 and 80% (follow-up 49.5 months). Five-year loco-regional control was 90.3%, and five-year distant metastases-free survival was 85%. Conclusions: Neoadjuvant chemotherapy with such protocol represents a feasible, efficient treatment for patients with A-NPC, ensuring excellent loco-regional disease control and overall survival with low incidence of distant metastases.

Original languageEnglish
Pages (from-to)1027-1034
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • Carboplatin
  • Chemoradiation
  • Nasopharyngeal carcinoma
  • Neoadjuvant chemotherapy
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this